NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $0.37 -0.02 (-5.43%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$0.37 +0.00 (+1.03%) As of 10/30/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Neumora Therapeutics Stock (NASDAQ:NMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$0.35▼$0.4150-Day Range$0.35▼$1.6352-Week Range$0.32▼$3.65Volume1.11 million shsAverage Volume1.92 million shsMarket Capitalization$69.00 millionP/E RatioN/ADividend YieldN/APrice Target$6.57Consensus RatingModerate Buy Company Overview Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders. Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure. The company has also pursued additional programs for disorders of the central nervous system, supported by its data-driven NeuroDiscovery platform. Neumora was founded in 2019 and is headquartered in Watertown, Massachusetts. The company became a publicly traded business on the Nasdaq under the symbol NMRA in 2023. Its operations and clinical development activities are primarily centered in the United States, with clinical research conducted through relevant international study sites as applicable. Henry Gosebruch serves as chief executive officer.AI Generated. May Contain Errors. Read More Neumora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreNMRA MarketRank™: 3.91207931124 of 5 starsNeumora Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 95th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeumora Therapeutics has a consensus price target of $6.57, representing about 1,689.6% upside from its current price of $0.37.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neumora Therapeutics are expected to grow in the coming year, from ($0.83) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.11% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 2.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 15.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.60 News SentimentNeumora Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neumora Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for NMRA on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,219.00 in company stock.Percentage Held by Insiders26.94% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMRA Stock News HeadlinesNeumora Therapeutics Faces Nasdaq Minimum Bid Price WarningOctober 30 at 5:10 PM | tipranks.comNeumora Therapeutics Inc NMRAOctober 14, 2026 | morningstar.comMThe government is buying stocksDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 1 at 1:00 AM | Porter & Company (Ad)Neumora Therapeutics, Inc. (NMRA)September 15, 2026 | finance.yahoo.comTop Neumora Executive Makes Notable Move With Insider Stock SaleAugust 21, 2026 | tipranks.comNeumora Therapeutics Announces CEO Transition and Q2 ResultsAugust 14, 2026 | tipranks.comNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comNeumora Therapeutics Shares Rise on Positive Obesity Drug ResultsJuly 28, 2026 | marketwatch.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $1.79 on January 1st, 2026. Since then, NMRA stock has decreased by 79.5% and is now trading at $0.3672. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its earnings results on Friday, August, 14th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at a price of $16.00-$18.00 per share. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Costco Wholesale (COST), Amicus Therapeutics (FOLD), Pfizer (PFE), Immunic (IMUX) and Diamondback Energy (FANG). Company Calendar Last Earnings8/14/2026Today11/01/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NMRA's financial health is in the Red zone, according to TradeSmith. NMRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NMRA CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees63Year Founded2020Price Target and Rating Average Price Target for Neumora Therapeutics$6.57 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+1,689.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$236.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-242.28% Return on Assets-131.32% Debt Debt-to-Equity Ratio1.19 Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book0.59Miscellaneous Outstanding Shares187,900,000Free Float137,277,000Market Cap$69.00 million OptionableOptionable Beta2.95 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:NMRA) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
